ROCKVILLE, Md., Aug. 1, 2022
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that
it will host a conference call on Wednesday,
August 3, 2022, at 4:30 p.m.
ET to discuss its financial results for the quarter ended
June 30, 2022, and recent operational
highlights.
Listeners can register for the webcast via this link. Analysts
wishing to participate in the question and answer session should
use this link. A replay of the webcast will be available via the
company's investor website approximately two hours after the call's
conclusion. Those who plan on particpating are advised to join 15
minutes prior to the start time.
About REGENXBIO
Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates,
including late-stage and commercial programs, in multiple
therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to
progress five AAV Therapeutics from our internal pipeline and
licensed programs into pivotal-stage or commercial products by
2025.
Contacts:
Dana
Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-august-3-to-discuss-second-quarter-2022-financial-results-and-recent-operational-highlights-301596706.html
SOURCE REGENXBIO Inc.